Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age9-64
SponsorStanford University
About this trial
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Eligibility criteria
Qualifiers
Age 9 through 64 years
Diagnosed with COVID-19 at least 2 months prior enrollment
Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
Patients without COVID-19 diagnosis for controls
Disqualifiers
Received the influenza vaccine less than 4 months ago
Pregnant or lactating
Patients with special risks attendant to venipuncture
Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
Trial design
Treatments tested in this trial
- Flu shot
Treatment groups
230 Participants
are divided into 2 treatment groupsSponsors and collaborators
Stanford University
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Source ClinicalTrials.gov